Oculis (OCS) Competitors $29.49 -1.51 (-4.87%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$29.48 -0.01 (-0.05%) As of 05/22/2026 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. KYMR, PTGX, LNTH, TGTX, and RYTMShould you buy Oculis stock or one of its competitors? MarketBeat compares Oculis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oculis include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Lantheus (LNTH), TG Therapeutics (TGTX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. OCS vs. KYMROCS vs. PTGXOCS vs. LNTHOCS vs. TGTXOCS vs. RYTMHow does Oculis compare to Kymera Therapeutics?Oculis (NASDAQ:OCS) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Which has more risk & volatility, OCS or KYMR? Oculis has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, meaning that its stock price is 106% more volatile than the broader market. Do analysts rate OCS or KYMR? Oculis currently has a consensus target price of $49.38, indicating a potential upside of 67.43%. Kymera Therapeutics has a consensus target price of $118.10, indicating a potential upside of 49.70%. Given Oculis' higher possible upside, research analysts plainly believe Oculis is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Kymera Therapeutics 1 Sell rating(s) 0 Hold rating(s) 20 Buy rating(s) 1 Strong Buy rating(s) 2.95 Does the media refer more to OCS or KYMR? In the previous week, Oculis had 3 more articles in the media than Kymera Therapeutics. MarketBeat recorded 5 mentions for Oculis and 2 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.84 beat Oculis' score of 0.50 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, OCS or KYMR? Oculis has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$1.45M1,179.19-$119.44M-$2.13N/AKymera Therapeutics$39.21M165.51-$311.35M-$3.57N/A Is OCS or KYMR more profitable? Kymera Therapeutics has a net margin of -611.94% compared to Oculis' net margin of -8,460.67%. Kymera Therapeutics' return on equity of -24.71% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,460.67% -56.78% -45.62% Kymera Therapeutics -611.94%-24.71%-22.05% Do institutionals & insiders hold more shares of OCS or KYMR? 22.3% of Oculis shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryKymera Therapeutics beats Oculis on 9 of the 16 factors compared between the two stocks.How does Oculis compare to Protagonist Therapeutics?Oculis (NASDAQ:OCS) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk. Is OCS or PTGX more profitable? Protagonist Therapeutics has a net margin of -154.88% compared to Oculis' net margin of -8,460.67%. Protagonist Therapeutics' return on equity of -17.76% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,460.67% -56.78% -45.62% Protagonist Therapeutics -154.88%-17.76%-16.47% Which has better earnings & valuation, OCS or PTGX? Oculis has higher earnings, but lower revenue than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$1.45M1,179.19-$119.44M-$2.13N/AProtagonist Therapeutics$46.02M138.61-$130.15M-$1.81N/A Which has more risk and volatility, OCS or PTGX? Oculis has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Does the media prefer OCS or PTGX? In the previous week, Protagonist Therapeutics had 3 more articles in the media than Oculis. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 5 mentions for Oculis. Protagonist Therapeutics' average media sentiment score of 0.60 beat Oculis' score of 0.50 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in OCS or PTGX? 22.3% of Oculis shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate OCS or PTGX? Oculis presently has a consensus target price of $49.38, suggesting a potential upside of 67.43%. Protagonist Therapeutics has a consensus target price of $115.21, suggesting a potential upside of 16.16%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Protagonist Therapeutics 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88 SummaryProtagonist Therapeutics beats Oculis on 11 of the 16 factors compared between the two stocks.How does Oculis compare to Lantheus?Lantheus (NASDAQ:LNTH) and Oculis (NASDAQ:OCS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Which has better valuation & earnings, LNTH or OCS? Lantheus has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.54B4.35$233.56M$4.1524.82Oculis$1.45M1,179.19-$119.44M-$2.13N/A Is LNTH or OCS more profitable? Lantheus has a net margin of 18.05% compared to Oculis' net margin of -8,460.67%. Lantheus' return on equity of 29.32% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Lantheus18.05% 29.32% 15.00% Oculis -8,460.67%-56.78%-45.62% Do institutionals & insiders believe in LNTH or OCS? 99.1% of Lantheus shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor LNTH or OCS? In the previous week, Lantheus and Lantheus both had 5 articles in the media. Oculis' average media sentiment score of 0.50 beat Lantheus' score of 0.28 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, LNTH or OCS? Lantheus has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, Oculis has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Do analysts recommend LNTH or OCS? Lantheus currently has a consensus price target of $99.71, indicating a potential downside of 3.19%. Oculis has a consensus price target of $49.38, indicating a potential upside of 67.43%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73Oculis 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 SummaryLantheus beats Oculis on 10 of the 16 factors compared between the two stocks.How does Oculis compare to TG Therapeutics?Oculis (NASDAQ:OCS) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability. Is OCS or TGTX more profitable? TG Therapeutics has a net margin of 65.95% compared to Oculis' net margin of -8,460.67%. TG Therapeutics' return on equity of 88.73% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,460.67% -56.78% -45.62% TG Therapeutics 65.95%88.73%43.44% Do institutionals and insiders believe in OCS or TGTX? 22.3% of Oculis shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend OCS or TGTX? Oculis currently has a consensus target price of $49.38, indicating a potential upside of 67.43%. TG Therapeutics has a consensus target price of $52.50, indicating a potential upside of 35.07%. Given Oculis' stronger consensus rating and higher probable upside, research analysts clearly believe Oculis is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89TG Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57 Does the media refer more to OCS or TGTX? In the previous week, Oculis had 3 more articles in the media than TG Therapeutics. MarketBeat recorded 5 mentions for Oculis and 2 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.85 beat Oculis' score of 0.50 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, OCS or TGTX? Oculis has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Which has higher earnings and valuation, OCS or TGTX? TG Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$1.45M1,179.19-$119.44M-$2.13N/ATG Therapeutics$616.29M9.65$447.18M$2.8613.59 SummaryTG Therapeutics beats Oculis on 11 of the 16 factors compared between the two stocks.How does Oculis compare to Rhythm Pharmaceuticals?Oculis (NASDAQ:OCS) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership. Which has preferable valuation & earnings, OCS or RYTM? Oculis has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$1.45M1,179.19-$119.44M-$2.13N/ARhythm Pharmaceuticals$189.76M31.72-$196.54M-$3.13N/A Do institutionals & insiders hold more shares of OCS or RYTM? 22.3% of Oculis shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is OCS or RYTM more profitable? Rhythm Pharmaceuticals has a net margin of -93.33% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,460.67% -56.78% -45.62% Rhythm Pharmaceuticals -93.33%-203.25%-44.99% Does the media refer more to OCS or RYTM? In the previous week, Oculis had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for Oculis and 1 mentions for Rhythm Pharmaceuticals. Oculis' average media sentiment score of 0.50 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, OCS or RYTM? Oculis has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Do analysts recommend OCS or RYTM? Oculis currently has a consensus target price of $49.38, suggesting a potential upside of 67.43%. Rhythm Pharmaceuticals has a consensus target price of $131.81, suggesting a potential upside of 50.06%. Given Oculis' stronger consensus rating and higher probable upside, equities analysts clearly believe Oculis is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Rhythm Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.84 SummaryOculis beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition ExportMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.71B$3.38B$6.44B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-13.8518.9321.2625.66Price / Sales1,179.19323.66556.8487.68Price / CashN/A125.9643.6856.73Price / Book6.817.1110.367.14Net Income-$119.44M$24.45M$3.56B$335.80M7 Day Performance-2.64%3.32%5.12%3.02%1 Month Performance11.54%2.52%3.54%2.48%1 Year Performance55.13%63.09%34.14%35.08% Oculis Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis3.0759 of 5 stars$29.49-4.9%$49.38+67.4%+55.1%$1.71B$1.45MN/A2Analyst UpgradeKYMRKymera Therapeutics2.5529 of 5 stars$78.59-1.4%$118.10+50.3%+167.5%$6.47B$39.21MN/A170PTGXProtagonist Therapeutics2.7273 of 5 stars$99.41-1.3%$113.69+14.4%+117.2%$6.39B$46.02MN/A120Analyst UpgradeAnalyst RevisionLNTHLantheus2.0513 of 5 stars$93.63+0.5%$99.71+6.5%+39.5%$6.10B$1.54B22.591,193TGTXTG Therapeutics4.3532 of 5 stars$39.67+0.5%$52.50+32.4%+12.4%$6.07B$616.29M13.86290 Related Companies and Tools Related Companies KYMR Competitors PTGX Competitors LNTH Competitors TGTX Competitors RYTM Competitors MIRM Competitors CNTA Competitors PTCT Competitors SYRE Competitors SRRK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
